Published Scientific Articles
NP-ALT, a Liposomal:Peptide Drug, Blocks p27Kip1 Phosphorylation to Induce Oxidative Stress, Necroptosis, and Regression in Therapy-Resistant Breast Cancer Cells
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
Tyrosine Phosphorylation of p27Kip1 Correlates with Palbociclib Responsiveness in Breast Cancer Tumor Cells Grown in Explant Culture
Concarlo in the News
Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway
Many startups are built off research, so why don’t more scientists become founders?
CDK Inhibitors: Why Women – and Men – Should Know About This ‘New Era’ Of Cancer Treatment
Breast Cancer Deserves More Than A Month
Webinars & Talks
Stacy Blain and Arthur Klausner on NewYorkBIOs Virtual Breakfast Series
Heroes of Healthcare – Episode 50: Shutting the Door on Cancer Cells
Beyond Biotech podcast 24: Concarlo Therapeutics
LabOps: Changing Outcomes for Drug-Resistant Patients with Stacy Blain, Founder, and CSO at Concarlo Therapeutics
Awards
“The reward for work well done is the opportunity to do more”
—Jonas Salk
RESI’s Innovator’s Pitch Challenge Winner
Princeton University Women’s Showcase
The 50 Most admired companies: CIO Bio
Top 100 entreprenuers: Alumni List
Top Biotech Startup 2022
Awarded by: Life Sciences Review
